Functional Consequences of Cognitive Impairment
Project Description |
Faculty and Staff |
 |
Advances in the Past Year |
Publications | |
|
||
Andrew Siderowf, MD, MSCEProject Description
Methods for evaluating cognitive dysfunction in Parkinson’s disease (PD) and Parkinson’s disease dementia (PDD) have been largely borrowed from approaches developed for other dementing disorders, particularly Alzheimer’s disease. PD patients, however, have a specific profile of cognitive and motor impairments that differs from Alzheimer’s disease.
As a result, a methodology specific to PD is needed to accurately classify cognitive features and to assess the impact of potential interventions. The purpose of this project is to address one aspect of this gap by developing a new clinical measurement tool, the “Functional Consequences of Cognitive Impairment” (FCCI) scale. The study and development of this scale has three aims: 1) to conduct qualitative studies to define specifically the functional consequences of cognitive impairment in PD; 2) to conduct detailed psychometric evaluations of the new FCCI; 3) to assess the validity of the FCCI in a longitudinal cohort study of PD patients. The study will produce a reliable measure of the impact of cognitive impairments in basic and instrumental daily functioning in PD and PDD patients. This instrument will also be valuable in clinical trials of cognitive interventions designed to treat or prevent PD.
Significant Scientific Advances in the Past Year
The study findings from this past year will result in the development of a feasible, reliable and valid rating scale that measures the functional consequences of cognitive impairment PD. This instrument will be suitable for use in clinical trials of interventions designed to treat the cognitive impairments in PD, and will lead to a better understanding of the functional consequences of PD.
Faculty and Staff
Faculty Andrew Siderowf, MD, MSCE
Project Leader Henry A. Glick, PhD Judy Shea, PhD Jason Karlawish, MD Daniel Weintraub, MD Staff Jacqui Rick Katia Duey, Research Coordinator Gene Peir, Research Coordinator
Publications
- Siderowf, A., Xie, S.X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., Shaw, L.M., Van Deerlin, V., Trojanowski, J.Q., and Clark, C.M. CSF amyloid β 1-42 predicts cognitive decline in Parkinson’s disease. Neurol., 75:1055-1061, 2010.
- Chen-Plotkin, A., Hu,W.T., Siderowf, A., Weintraub, D, Goldmann Gross, R., Hurtig, H.I., Xie, S., Arnold, S.E., Grossman,M., Clark, C.M., Shaw, L.M., McCluskey, L., Elman, L.,Karlawish, J., Van Deerlin, V.M., Lee, V.M.-Y., Soares, H., and Trojanowski, J.Q. Plasma EGF levels correlate with cognitive performance and predict cognitive impairment in Parkinson’s disease. Ann. Neurol., In press, 2010.
- Hu,W.T., Chen-Plotkin, A., Arnold, S.E., Grossman,M., Clark, C.M., Shaw, L.M., McCluskey, L., Elman, L., Karlawish, J., Hurtig, H.I., Siderowf, A., Lee, V.M.-Y., Soares, H., and Trojanowski, J.Q. Biomarker discovery for Alzheimer’s disease, frontotemporal lobar degeneration, and Parkinson’s disease. Acta Neuropathol., 120:385-399, 2010.
- Moural C, Brennan L, Rosenthal R, Clark C, Duda J, Hurtig H, Siderowf A. 2008 Safety and Tolerability of Research Lumbar Punctures in Patients with Parkinson’s Disease. Symposium on the Etiology, Pathogenesis and Treatment of Parkinson’s Disease. Salt Lake City, Utah, September 2008. Click to view poster.
- Rosenthal E, Brennan L, Milber J, Hurtig H, Weintraub W, Siderowf A. Impact of Mild Cognitive Deficits on Daily Functioning in Parkinson’s Disease. Movement Disorders Society Poster, Chicago, IL, June 2008. Click to view poster.
- Rosenthal E, Brennan L, Milber J, Hurtig H, Weintraub D, Siderowf A. Impact of Mild Cognitive Deficits on Daily Functioning in Parkinson’s Disease. IOA Retreat Poster 2008, Philadelphia, PA, May 2008.
- Siderowf A, Jaggi J, Xie SX, Loveland-Jones C, Leng L, Hurtig H, Colcher A, Stern M, Chou CL, Liang G, Maccarone H, Simuni T, Baltuch G. Long-term effects of bilateral sub-thalamic nucleus stimulation on health-related quality-of-life in advanced Parkinson’s disease. Movement Disorders. 21: 746-753, 2006.
- Dahodwala N, Connolly J, Farmer J, Stern MB, Jennings D, Siderowf A. Interest in predictive testing for Parkinson’s disease: Impact of neuroprotective therapy. Parkinsonism and Related Disorders (in press).
- Weintraub D, Xie S, Karlawish J, Siderowf A. Differences in Depression Symptoms in Patients with Alzheimer’s and Parkinson’s Diseases: Evidence From the 15-Item Geriatric Depression Scale (GDS-15). International Journal of Geriatric Psychiatry. (in press).
- Weintraub D, Hurtig H. Presentation and Management of Psychosis in Parkinson’s Disease and Dementia with Lewy Bodies. Am J Psych (in press)